Japan market screening · Molecule
モンテルカストナトリウム · JAN (Japanese Accepted Name)
Other antiallergic agents · 6 presentations · oral · Supply status as of 28 Aug 2026 · Prescription data FY2024 (Apr 2024 – Mar 2025)
One block is one marketed product. Every company that markets this molecule in Japan reports its supply status to the Ministry of Health, Labour and Welfare, and we publish that report the day it changes.
National dispensed volume, FY2014 – FY2024. Source: NDB Open Data.
Figures are in hundreds of millions of units. The reporting scope was widened in FY2022, so levels before and after that year are not directly comparable — the step up between FY2021 and FY2022 is partly definitional. Demand peaks in March every year.
These are Japanese regulatory categories. They do not map one-to-one onto the FDA or EMA definition of a shortage, and the difference matters.
| Status | Products | Japanese term |
|---|---|---|
| Normal supply Shipping without restriction. | 45 | 通常出荷 |
| Limited supply Shipments are being restricted or allocated. The product is still available, but a buyer cannot get as much as they ask for. Japan reports the cause separately: a problem at the company itself, demand shifted from a competitor's product, or another cause. | 18 | 限定出荷 |
| Supply suspended Shipments have stopped. This is not discontinuation — supply may resume. A product that is being withdrawn for good is reported separately as 販売中止 (discontinued). | 10 | 供給停止 |
Share of national dispensed volume by prefecture, FY2024. Estimated from NDB Open Data.
| Prefecture | Share | Units |
|---|---|---|
| Tokyo | 14.2% | 140m |
| Kanagawa | 8.9% | 88.8m |
| Osaka | 6.3% | 63.5m |
| Saitama | 5.9% | 58.6m |
| Aichi | 5.7% | 56.7m |
Raw prefecture volume mostly reflects population. To see where this molecule is used more than the country as a whole would predict, ask us for the location quotient — it is part of the screening dataset below.
Most generic products in Japan are listed under a unified non-proprietary name (統一名収載): several companies' products share a single code on the national price list. Public statistics are aggregated at that code, so volume and value cannot be split back out by company or by brand. Anyone offering you Japanese brand share is either using proprietary distributor sales data, or estimating. We tell you which of the two it is before you buy.
Available as a commissioned extract, delivered in Excel. One row per molecule, 24 fields, plus a detail sheet per molecule.
Other antiallergic agents, ranked by annual demand at NHI list price.
Pages for these are in preparation. In the meantime, the molecule list shows how many products compete for each and how many of them are currently constrained.
Tell us the molecules or the area you are looking at. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).